AutoDx-DR Prospective Clinical Validation Study Protocol
Diabetic Retinopathy
About this trial
This is an interventional diagnostic trial for Diabetic Retinopathy focused on measuring Diabetic Retinopathy
Eligibility Criteria
Inclusion Criteria:
A documented diagnosis of diabetes mellitus in accordance with the criteria established by the American Diabetes Association (ADA)7 as indicated by at least one of the following:
- Hemoglobin A1c (HbA1c) > 6.5%
- Fasting Plasma Glucose (FPG; period of fasting must be at least 8 hours) > 126 mg/dL (7.0 mmol/L)
Oral Glucose Tolerance Test (OGTT) with 2-hour plasma glucose >200 mg/dL (11.1 mmol/L), using the equivalent of an oral 75 g anhydrous glucose dose dissolved in water o Symptoms of hyperglycemia or hyperglycemic crisis with a random plasma glucose (RPG) ≥ 200 mg/dL (11.1 mmol/L)
- 22 years of age or older
- Ability to understand the study and sign the informed consent
Exclusion Criteria:
A documented diagnosis of more than mild diabetic retinopathy in the patient record.
o More than mild diabetic retinopathy shall be defined as moderate NPDR, severe NPDR, proliferative diabetic retinopathy (PDR) or any level of DME; or a documented diabetic eye exam report indicating more than microaneurysms [i.e. presence of intraretinal hemorrhages, venous beading, intraretinal microvascular abnormalities (IRMA,) neovascularization or DME.]
- They report having severe vision loss in both eyes.
- They report a history of laser treatment or surgery of the retina.
- They report that they are currently receiving treatment for DR or DME.
- They report a diagnosis of angle closure glaucoma.
- They report hypersensitivity to light which makes retinal imaging uncomfortable.
- They are currently pregnant or breastfeeding.
- They report that they have an iris supported intraocular lens or anterior chamber intraocular lens associated with a previous cataract surgery.
- They had a previous pupilloplasty surgery.
Sites / Locations
Arms of the Study
Arm 1
Experimental
AutoDX and Gold Standard
A licensed clinician will obtain 60° wide single-field retinal fundus images from subjects who are diabetic patients in primary care environments (i.e. non-eye care settings, such as internal medicine, family medicine, and endocrinology). The fundus images will be uploaded to the RetinaVue Network software using the AutoDx-DR with Over-read modality, where images are transmitted to both AutoDx-DR and a remote ophthalmologist. Subjects participating in this study will undergo further retinal fundus imaging: four mydriatic, stereoscopic 45° field of view (4W) retinal images and spectral domain optical coherence tomography (SD-OCT) captured with the Reference Standard Camera